We will evaluate 215 MCI patients with non-ceruloplasmin copper >1.6 μmol/L (normal reference range 0.1–1.6 μmol/L; [4]) and positive for AD related cerebrospinal fluid biomarkers (peptides Aβ, tau, p-tau) or for the presence of Cerebral Amyloidosis evaluated by Florbetapir (18-F)-Positron emission tomography. Here, MAPT is linked to Alzheimer disease.